Investors News Releases Sign up for email alerts to receive company and investor updates News Releases Investor Relations Investor Relations News Releases Presentations & Events Common Stock Information Stock Quote & Chart Analyst Coverage SEC Filings Corporate Governance Overview Board of Directors Committee Composition Management Team Annual Reports News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Feb 13 2007 Cyclacel Pharmaceuticals announces $36 million registered direct financing Feb 07 2007 Cyclacel Pharmaceuticals to present at 2007 Bio CEO & Investor Conference Feb 05 2007 Cyclacel announces development plan for its seliciclib CDK inhibitor to treat nasopharyngeal cancer Jan 30 2007 Cyclacel Pharmaceuticals, Inc. announces quarterly dividends for 6% convertible exchangeable preferred stock Dec 13 2006 Cyclacel submits IND of CYC116 an Aurora kinase and VEGRF2 inhibitor to treat cancer Dec 06 2006 Cyclacel Pharmaceuticals to present at NYSSA 10th annual Biotech/Speciality Pharma Industry Conference Nov 28 2006 Cyclacel reports interim Phase I data for sapacitabine in patients with advanced leukemias or myelodysplastic syndromes Nov 17 2006 Cyclacel Pharmaceuticals to present at Lazard Capital Markets Life Sciences Conference Nov 13 2006 Cyclacel Pharmaceuticals reports third quarter 2006 financial results Nov 10 2006 Cyclacel reports Phase I sapacitabine study results at 18th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics meeting Nov 06 2006 Cyclacel Pharmaceuticals to announce third quarter 2006 financial results on November 13, 2006 Oct 30 2006 Cyclacel Pharmaceuticals to present at Rodman & Renshaw annual healthcare conference Oct 24 2006 Cyclacel Pharmaceuticals names John Womelsdorf, Ph.D., Vice President, Business Development Oct 24 2006 Cyclacel Pharmaceuticals to present at C.E. Unterberg, Towbin Emerging Opportunities in Healthcare Conference Oct 23 2006 Cyclacel Pharmaceuticals, Inc. announces quarterly dividend for 6% Convertible Exchangeable Preferred Stock Sep 05 2006 Cyclacel Pharmaceuticals to present at Thomson Financial and Biocentury's: NewsMakers in the Biotech Industry Conference Aug 14 2006 Cyclacel Pharmaceuticals Reports Second Quarter 2006 Financial Results Jul 19 2006 Cyclacel Pharmaceuticals, Inc. Announces Quarterly Dividend For 6% Convertible Exchangeable Preferred Stock Jun 29 2006 Cyclacel Begins A Phase IIb Randomized Trial Of Seliciclib For Previously Treated Non-Small Cell Lung Cancer Jun 15 2006 Cyclacel Begins Phase I Pharmacologic Study Of Oral Sapacitabine In Patients With Advanced Leukemias Jun 12 2006 Cyclacel Pharmaceuticals To Present At 5th Annual Needham & Company, LLC Biotechnology & Medical Technology Conference 2006 May 18 2006 Cyclacel Boosts Clinical Work With $45M Private Placement May 18 2006 Cyclacel Pharmaceuticals To Present At Bioequity Europe 2006 May 04 2006 Cyclacel Pharmaceuticals To Present At Rodman And Renshaw 3rd Annual Global Healthcare Conference Apr 27 2006 Cyclacel Pharmaceuticals Announces $45 Million Private Placement Pagination First page « first Previous page ‹ previous … Page 13 Page 14 Page 15 Page 16 Page 17 Page 18 Page 19 Current page 20 Page 21 Next page next › Last page last » Toolkit Email AlertsRSS FeedsPrint Page
News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Feb 13 2007 Cyclacel Pharmaceuticals announces $36 million registered direct financing Feb 07 2007 Cyclacel Pharmaceuticals to present at 2007 Bio CEO & Investor Conference Feb 05 2007 Cyclacel announces development plan for its seliciclib CDK inhibitor to treat nasopharyngeal cancer Jan 30 2007 Cyclacel Pharmaceuticals, Inc. announces quarterly dividends for 6% convertible exchangeable preferred stock Dec 13 2006 Cyclacel submits IND of CYC116 an Aurora kinase and VEGRF2 inhibitor to treat cancer Dec 06 2006 Cyclacel Pharmaceuticals to present at NYSSA 10th annual Biotech/Speciality Pharma Industry Conference Nov 28 2006 Cyclacel reports interim Phase I data for sapacitabine in patients with advanced leukemias or myelodysplastic syndromes Nov 17 2006 Cyclacel Pharmaceuticals to present at Lazard Capital Markets Life Sciences Conference Nov 13 2006 Cyclacel Pharmaceuticals reports third quarter 2006 financial results Nov 10 2006 Cyclacel reports Phase I sapacitabine study results at 18th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics meeting Nov 06 2006 Cyclacel Pharmaceuticals to announce third quarter 2006 financial results on November 13, 2006 Oct 30 2006 Cyclacel Pharmaceuticals to present at Rodman & Renshaw annual healthcare conference Oct 24 2006 Cyclacel Pharmaceuticals names John Womelsdorf, Ph.D., Vice President, Business Development Oct 24 2006 Cyclacel Pharmaceuticals to present at C.E. Unterberg, Towbin Emerging Opportunities in Healthcare Conference Oct 23 2006 Cyclacel Pharmaceuticals, Inc. announces quarterly dividend for 6% Convertible Exchangeable Preferred Stock Sep 05 2006 Cyclacel Pharmaceuticals to present at Thomson Financial and Biocentury's: NewsMakers in the Biotech Industry Conference Aug 14 2006 Cyclacel Pharmaceuticals Reports Second Quarter 2006 Financial Results Jul 19 2006 Cyclacel Pharmaceuticals, Inc. Announces Quarterly Dividend For 6% Convertible Exchangeable Preferred Stock Jun 29 2006 Cyclacel Begins A Phase IIb Randomized Trial Of Seliciclib For Previously Treated Non-Small Cell Lung Cancer Jun 15 2006 Cyclacel Begins Phase I Pharmacologic Study Of Oral Sapacitabine In Patients With Advanced Leukemias Jun 12 2006 Cyclacel Pharmaceuticals To Present At 5th Annual Needham & Company, LLC Biotechnology & Medical Technology Conference 2006 May 18 2006 Cyclacel Boosts Clinical Work With $45M Private Placement May 18 2006 Cyclacel Pharmaceuticals To Present At Bioequity Europe 2006 May 04 2006 Cyclacel Pharmaceuticals To Present At Rodman And Renshaw 3rd Annual Global Healthcare Conference Apr 27 2006 Cyclacel Pharmaceuticals Announces $45 Million Private Placement Pagination First page « first Previous page ‹ previous … Page 13 Page 14 Page 15 Page 16 Page 17 Page 18 Page 19 Current page 20 Page 21 Next page next › Last page last »
Feb 05 2007 Cyclacel announces development plan for its seliciclib CDK inhibitor to treat nasopharyngeal cancer
Jan 30 2007 Cyclacel Pharmaceuticals, Inc. announces quarterly dividends for 6% convertible exchangeable preferred stock
Dec 06 2006 Cyclacel Pharmaceuticals to present at NYSSA 10th annual Biotech/Speciality Pharma Industry Conference
Nov 28 2006 Cyclacel reports interim Phase I data for sapacitabine in patients with advanced leukemias or myelodysplastic syndromes
Nov 10 2006 Cyclacel reports Phase I sapacitabine study results at 18th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics meeting
Nov 06 2006 Cyclacel Pharmaceuticals to announce third quarter 2006 financial results on November 13, 2006
Oct 24 2006 Cyclacel Pharmaceuticals names John Womelsdorf, Ph.D., Vice President, Business Development
Oct 24 2006 Cyclacel Pharmaceuticals to present at C.E. Unterberg, Towbin Emerging Opportunities in Healthcare Conference
Oct 23 2006 Cyclacel Pharmaceuticals, Inc. announces quarterly dividend for 6% Convertible Exchangeable Preferred Stock
Sep 05 2006 Cyclacel Pharmaceuticals to present at Thomson Financial and Biocentury's: NewsMakers in the Biotech Industry Conference
Jul 19 2006 Cyclacel Pharmaceuticals, Inc. Announces Quarterly Dividend For 6% Convertible Exchangeable Preferred Stock
Jun 29 2006 Cyclacel Begins A Phase IIb Randomized Trial Of Seliciclib For Previously Treated Non-Small Cell Lung Cancer
Jun 15 2006 Cyclacel Begins Phase I Pharmacologic Study Of Oral Sapacitabine In Patients With Advanced Leukemias
Jun 12 2006 Cyclacel Pharmaceuticals To Present At 5th Annual Needham & Company, LLC Biotechnology & Medical Technology Conference 2006
May 04 2006 Cyclacel Pharmaceuticals To Present At Rodman And Renshaw 3rd Annual Global Healthcare Conference
